Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.

Walsh AJ, Cook RS, Sanders ME, Aurisicchio L, Ciliberto G, Arteaga CL, Skala MC
Cancer Res. 2014 74 (18): 5184-94

PMID: 25100563 · PMCID: PMC4167558 · DOI:10.1158/0008-5472.CAN-14-0663

There is a need for technologies to predict the efficacy of cancer treatment in individual patients. Here, we show that optical metabolic imaging of organoids derived from primary tumors can predict the therapeutic response of xenografts and measure antitumor drug responses in human tumor-derived organoids. Optical metabolic imaging quantifies the fluorescence intensity and lifetime of NADH and FAD, coenzymes of metabolism. As early as 24 hours after treatment with clinically relevant anticancer drugs, the optical metabolic imaging index of responsive organoids decreased (P < 0.001) and was further reduced when effective therapies were combined (P < 5 × 10(-6)), with no change in drug-resistant organoids. Drug response in xenograft-derived organoids was validated with tumor growth measurements in vivo and staining for proliferation and apoptosis. Heterogeneous cellular responses to drug treatment were also resolved in organoids. Optical metabolic imaging shows potential as a high-throughput screen to test the efficacy of a panel of drugs to select optimal drug combinations. Cancer Res; 74(18); 5184-94. ©2014 AACR.

©2014 American Association for Cancer Research.

MeSH Terms (10)

Animals Breast Neoplasms Female Heterografts Humans Mice, Nude Optical Imaging Organoids Predictive Value of Tests Xenograft Model Antitumor Assays

Connections (3)

This publication is referenced by other Labnodes entities:

Links